AstraZeneca
Global biopharmaceutical company applying AI cell-atlas and generative-antibody platforms to oncology and inflammatory-disease target discovery.
- Company type
- Global pharmaceutical company
- Headquarters
- Cambridge, United Kingdom
- Website
- https://www.astrazeneca.com
- Profile last verified
- 2026-07-29
AI Partnerships & Deployments
- 2025-10-16 — Expanded IBD collaboration with Immunai (Immunai). AstraZeneca returned to long-term AI partner Immunai for a new deal to advance an undisclosed inflammatory bowel disease (IBD) target that Immunai had already identified via its AMICA cell atlas and Immunodynamics Engine AI model. AstraZeneca pays an upfront fee plus milestones, with the deal worth up to $85 million combined. Disclosed: Up to $85M combined. Source: Fierce Biotech (accessed 2026-07-29)
- 2023-12-04 — AI antibody collaboration with Absci (Absci). Collaboration to deliver an AI-designed therapeutic antibody against an oncology target using Absci's Integrated Drug Creation platform. Financial terms were not disclosed. Source: Absci press release (GlobeNewswire) (accessed 2026-07-29)